Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Receivables (2022 - 2025)

Historic Receivables for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to $115.1 million.

  • Arcutis Biotherapeutics' Receivables rose 9148.02% to $115.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.1 million, marking a year-over-year increase of 9148.02%. This contributed to the annual value of $73.1 million for FY2024, which is 18312.47% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Receivables stood at $115.1 million for Q3 2025, which was up 9148.02% from $106.7 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Receivables' 5-year high stood at $115.1 million during Q3 2025, with a 5-year trough of $2.4 million in Q3 2022.
  • Its 4-year average for Receivables is $46.7 million, with a median of $37.2 million in 2024.
  • Its Receivables has fluctuated over the past 5 years, first skyrocketed by 69872.48% in 2023, then surged by 9148.02% in 2025.
  • Quarter analysis of 4 years shows Arcutis Biotherapeutics' Receivables stood at $8.5 million in 2022, then skyrocketed by 205.12% to $25.8 million in 2023, then surged by 183.12% to $73.1 million in 2024, then surged by 57.55% to $115.1 million in 2025.
  • Its last three reported values are $115.1 million in Q3 2025, $106.7 million for Q2 2025, and $85.4 million during Q1 2025.